by Mark Curtis | Feb 23, 2015
. Welcome to your deal review for the month of January. There was a mixed bag of news last month, which included financing activity, industry partnerships and research collaborations. The cell therapy tools industry was front and centre as NeoStem and Invetech struck...
by Stacey Johnson | Feb 20, 2015
. If you haven’t heard the name Janet Rossant, my guess is that you aren’t part of the stem cell community or you spend a little too much time in the lab. Dr. Rossant is Chief of Research at the Hospital for Sick Children in Toronto, Canada and she leads the new...
by Mark Curtis | Feb 19, 2015
. Welcome to your Update from the Clinic for the month of January. Pluristem and OncoMed reported preliminary efficacy data from early-stage trials, while the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) granted a number of Orphan Drug...
by David Kent | Feb 9, 2015
> This article is the second in a series about the human capital created by the Network of Centre of Excellence known as the Stem Cell Network (SCN), which was created in 2001, will wind down the majority of it’s activities this year. The first article focused on...
by David Kent | Feb 2, 2015
> As many of our readers are aware, the Network of Centre of Excellence known as the Stem Cell Network (SCN), which was created in 2001, will wind down the majority of it’s activities this year. I have been a trainee/alumnus since the start of my PhD in 2003 and...
by James Smith | Jan 26, 2015
With contributions from David Brindley . Cell-based treatments are being developed and marketed for a variety of indications: from rare orphan diseases like graft versus host disease (GvHD), to blockbuster conditions like diabetes and cardiovascular disease that...
Comments